Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market
Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area.
Quick Answer
Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area.
Key Questions
- What specific practices is Biogen accused of in Italy?
- What are the potential penalties if Biogen is found guilty?
- How might this investigation affect the availability or pricing of Biogen's MS drugs?
- What is Biogen's typical response to such investigations?
Contents9 sections
Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market
Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area. For BD teams, investors, and analysts tracking neurology catalysts, the outcome warrants close monitoring as it intersects with patent cliffs, generic competition, and an increasingly scrutinized European pricing environment.
Key Takeaways
- Italy's Autorità Garante della Concorrenza e del Mercato (AGCM) has opened a formal investigation into Biogen Italia and its US parent for alleged abuse of a dominant position in the multiple sclerosis market, with a particular focus on pricing and market access conduct.
- The probe arrives as Biogen faces mounting competitive pressure: Tecfidera's original formulation lost patent protection in 2024, and Sandoz has entered with a generic version priced roughly 20% below Biogen's branded drug.
- An adverse finding could trigger fines, mandated changes to commercial practices, and reputational damage that complicates Biogen's regulatory and business development efforts across Europe.
- The investigation signals a broader trend of national antitrust authorities in Europe scrutinizing pharmaceutical pricing behavior, particularly where dominant incumbents face new generic or biosimilar entrants.
Italian Antitrust Authority Investigates Biogen for Market Abuse
Italy's competition watchdog, the AGCM, has launched an investigation into Biogen Italia S.r.l. and its Cambridge, Massachusetts-based parent company, Biogen Inc., over allegations of abusing a dominant position in the Italian multiple sclerosis market. The authority disclosed the opening of proceedings in a press release, citing concerns that Biogen may have engaged in anti-competitive pricing strategies designed to hinder the uptake of competing treatments as patents on its flagship MS therapies expired.
The investigation centers on conduct that the AGCM alleges was intended to restrict market access for lower-cost alternatives — particularly generic versions of Tecfidera (dimethyl fumarate), one of Biogen's highest-revenue MS drugs. According to the AGCM's public statement, Sandoz launched its generic dimethyl fumarate product in Italy at a price approximately 20% below Biogen's branded Tecfidera, yet Biogen's commercial practices allegedly sought to undermine the competitive impact of that entry.
Biogen's original Tecfidera formulation lost patent protection in 2024, opening the door for generic competition. The timing of the AGCM probe — coming shortly after Sandoz's market entry — suggests the authority is examining whether Biogen leveraged its entrenched prescriber relationships, rebate structures, or other commercial mechanisms to maintain market share in ways that crossed the line from aggressive competition into abuse of dominance under Article 102 of the Treaty on the Functioning of the European Union.
The AGCM has broad authority to investigate and sanction anti-competitive conduct. If the authority finds sufficient evidence, Biogen could face fines of up to 10% of global annual turnover, along with injunctions requiring changes to its Italian commercial practices. The investigation timeline is not fixed, but Italian antitrust proceedings of this nature typically take 12 to 24 months from opening to a final decision.
Biogen's Multiple Sclerosis Portfolio and Market Position
Biogen has long been a dominant force in multiple sclerosis treatment. The company's MS franchise has historically been anchored by three key products: Avonex (interferon beta-1a), approved in the late 1990s; Tysabri (natalizumab), a high-efficacy monoclonal antibody; and Tecfidera (dimethyl fumarate), which became one of the world's best-selling oral MS therapies after its 2013 launch.
Collectively, these drugs generated billions in annual revenue and cemented Biogen's position as the leading MS-focused biopharmaceutical company. Even as competition intensified from Roche's Ocrevus (ocrelizumab) and Novartis' Kesimpta (ofatumumab), Biogen retained substantial market share, particularly in the oral therapy segment where Tecfidera was a preferred first-line option for many neurologists.
The company has publicly articulated a commitment to advancing MS innovation beyond its legacy portfolio. Biogen's pipeline includes efforts aimed at neurorepair, remyelination, and addressing progressive forms of MS — areas of significant unmet need. The company has stated that its research strategy is focused on reversing disability and repairing damage, not merely slowing disease progression.
However, Biogen's history with its MS drugs is not without regulatory blemish. In 2022, the company agreed to pay $900 million to settle federal allegations that it violated the Anti-Kickback Statute by paying kickbacks to physicians to induce prescriptions of Avonex, Tysabri, and Tecfidera between 2009 and 2014. That settlement, one of the largest anti-kickback resolutions in pharmaceutical history, underscored the aggressive commercial tactics that accompanied Biogen's MS dominance — and provides relevant context for the AGCM's current scrutiny of the company's Italian market conduct.
Implications for Pharma Business Development and Regulatory Teams
For Biogen's business development team, the Italian antitrust probe introduces a layer of uncertainty at an already challenging inflection point. The company is actively seeking to diversify beyond its maturing MS franchise, with recent strategic emphasis on Alzheimer's disease (despite the controversial Aduhelm and Leqembi rollouts), depression, and immunology. An adverse antitrust finding in Italy could complicate partnership negotiations and licensing deals by raising counterparty concerns about Biogen's regulatory risk profile and commercial compliance standards.
The probe also has direct implications for Biogen's European regulatory strategy. National pricing and reimbursement authorities across the EU are increasingly coordinated in their scrutiny of pharmaceutical companies' market conduct. An AGCM finding of abuse could prompt parallel reviews by national competition authorities in France, Germany, or Spain — markets where Biogen also holds significant MS share. Regulatory teams should anticipate that the EMA and national health technology assessment bodies may factor antitrust outcomes into their evaluations of market access applications.
For the broader MS competitive landscape, the investigation sends a signal to all incumbents with dominant market positions facing generic or biosimilar entry. Companies like Roche, Novartis, and Sanofi — all with significant MS portfolios — should reassess their own pricing and market access strategies in European markets where antitrust enforcement is intensifying. The AGCM's willingness to open a formal probe against a major US pharma company suggests that national authorities are prepared to act on complaints from generic competitors and health systems concerned about drug costs.
Investor sentiment is another variable to watch. Biogen's stock has been under pressure from pipeline setbacks, the Alzheimer's franchise's uncertain trajectory, and the ongoing erosion of MS revenues. An antitrust investigation — particularly one that could result in substantial fines or forced changes to commercial practices in a key European market — adds a new overhang. Analysts modeling Biogen's European revenue should build in scenario analyses for potential fine exposure and market share erosion in Italy specifically.
Regulatory Landscape and Compliance Considerations
The Biogen investigation sits within a broader European regulatory environment that has grown increasingly assertive on pharmaceutical pricing and competition. The European Commission's Pharmaceutical Legislation Review, which culminated in a proposed overhaul of the EU's general pharmaceutical legislation in 2023, included provisions aimed at promoting competition and reducing barriers to generic and biosimilar market entry. National authorities like the AGCM are the enforcement arm of this policy direction.
Under Italian competition law, which mirrors EU Treaty provisions, a finding of abuse of dominance requires establishing that a company holds a dominant position in a relevant market and has engaged in conduct that restricts competition. Common abuses in the pharmaceutical context include predatory pricing, loyalty-inducing rebate schemes, and strategic patent litigation designed to delay generic entry. The AGCM's investigation will examine whether Biogen's conduct in the Italian MS market meets these criteria.
The potential consequences of an adverse finding are material. Fines can reach 10% of a company's worldwide annual turnover — a figure that for Biogen could amount to hundreds of millions of dollars. Beyond financial penalties, the AGCM can order behavioral remedies, including mandatory changes to pricing policies, discount structures, or contracting practices. In extreme cases, structural remedies such as forced licensing or divestiture are theoretically possible, though rare in pharmaceutical antitrust cases.
Biogen's compliance teams should take note of the European Commission's guidance on competitive practices in the pharmaceutical sector, as well as the European Competition Network's enforcement priorities. National authorities across the EU have signaled increasing willingness to investigate pricing conduct, and the AGCM's Biogen probe may serve as a test case for enforcement in the post-patent period.
For authoritative guidance on EU pharmaceutical regulation and competition enforcement, teams should consult the EMA's overview of national competent authorities and the European Commission's pharmaceutical sector inquiry findings. Biogen's SEC filings, accessible through the SEC's EDGAR database, provide the company's own risk factor disclosures related to regulatory and legal proceedings.
Frequently Asked Questions
What specific practices is Biogen accused of in Italy?
The AGCM has alleged that Biogen Italia and its US parent engaged in conduct constituting an abuse of a dominant position in the Italian multiple sclerosis market. While the authority's full evidentiary basis has not been made public, the investigation is understood to focus on pricing and commercial practices — including potential rebate structures, contracting arrangements, and market access strategies — that were designed to impede the competitive entry of generic dimethyl fumarate following the 2024 patent expiry of Tecfidera. Sandoz, which launched its generic at a roughly 20% discount to Biogen's branded price, is believed to have been a catalyst for the complaint that triggered the AGCM's investigation.
What are the potential penalties if Biogen is found guilty?
Under Italian and EU competition law, the AGCM can impose fines of up to 10% of a company's total worldwide annual turnover for abuse of dominance. For Biogen, which reported approximately $9.8 billion in total revenue in fiscal year 2024, the theoretical maximum fine exposure is substantial — though actual penalties are typically a fraction of the statutory maximum. Beyond monetary fines, the authority can mandate behavioral remedies, including changes to pricing policies, discounting practices, and commercial contracting. The investigation typically takes 12 to 24 months to reach a final decision.
How might this investigation affect the availability or pricing of Biogen's MS drugs?
In the near term, the investigation is unlikely to affect the availability of Tysabri, Tecfidera, or Avonex in Italy. However, if the AGCM orders behavioral remedies — such as restrictions on rebate structures or requirements to facilitate generic market entry — the competitive dynamics in the Italian MS market could shift. Generic competitors like Sandoz could gain market share more rapidly, potentially driving down overall treatment costs. For Biogen, mandated changes to commercial practices could reduce pricing flexibility not only in Italy but potentially in other European markets where national authorities take cues from AGCM enforcement actions.
What is Biogen's typical response to such investigations?
Biogen has not yet issued a detailed public statement specifically addressing the AGCM investigation. Historically, the company has taken a cooperative posture with regulatory and enforcement authorities while vigorously defending its commercial practices. In the $900 million anti-kickback settlement with the US Department of Justice, Biogen neither admitted nor denied the allegations — a common resolution approach in pharmaceutical enforcement actions. For the Italian probe, Biogen is likely to engage proactively with the AGCM, present evidence that its conduct was competitively legitimate, and seek to resolve the matter before a formal finding of infringement. The company's SEC filings will be the primary public source for material updates on the investigation's status and any financial reserves established in connection with potential penalties.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
